331. Poročilo o preskusu št.: LVG 2022-129 : vzorec št. 2022/00254Barbara Piškur, Maarten De Groot, Zina Devetak, Maša Zagorac, Nikica Ogris, 2022, izvedensko mnenje, arbitražna odločba Ključne besede: varstvo gozdov, morfološke analize, borov smolasti rak, Fusarium circinatum, Gibberella circinata, Pinus sp. Objavljeno v DiRROS: 23.09.2022; Ogledov: 509; Prenosov: 0 |
332. Poročilo o preskusu št.: LVG 2022-128 : vzorec št. 2022/00197Barbara Piškur, Andreja Kavčič, Zina Devetak, Špela Jagodic, Maša Zagorac, Nikica Ogris, 2022, izvedensko mnenje, arbitražna odločba Ključne besede: varstvo gozdov, morfološke analize, borov smolasti rak, Fusarium circinatum, Gibberella circinata, Pinus sp. Objavljeno v DiRROS: 23.09.2022; Ogledov: 538; Prenosov: 0 |
333. Poročilo o preskusu št.: LVG 2022-127 : vzorec št. 2022/00490Nikica Ogris, Zina Devetak, Maša Zagorac, Barbara Piškur, 2022, izvedensko mnenje, arbitražna odločba Ključne besede: varstvo gozdov, morfološke analize, Geosmithia morbida, bolezen tisočerih rakov, navadni oreh, Juglans regia Objavljeno v DiRROS: 23.09.2022; Ogledov: 527; Prenosov: 0 |
334. Potentiation of electrochemotherapy effectiveness by immunostimulation with IL-12 gene electrotransfer in mice is dependent on tumor immune statusKatja Uršič Valentinuzzi, Špela Kos, Urška Kamenšek, Maja Čemažar, Simona Miceska, Boštjan Markelc, Simon Buček, Barbara Starešinič, Veronika Kloboves-Prevodnik, Richard Heller, Gregor Serša, 2021, izvirni znanstveni članek Povzetek: Electrochemotherapy (ECT) exhibits high therapeutic effectiveness in the clinic, achieving up to 80% local tumor control but without a systemic (abscopal) effect. Therefore, we designed a combination therapy consisting of ECT via intratumoral application of bleomycin, oxaliplatin or cisplatin with peritumoral gene electrotransfer of a plasmid encoding interleukin-12 (p. t. IL-12 GET). Our hypothesis was that p. t. IL-12 GET potentiates the effect of ECT on local and systemic levels and that the potentiation varies depending on tumor immune status. Therefore, the combination therapy was tested in three immunologically different murine tumor models. In poorly immunogenic B16F10 melanoma, IL-12 potentiated the antitumor effect of ECT with biologically equivalent low doses of cisplatin, oxaliplatin or bleomycin. The most pronounced potentiation was observed after ECT using cisplatin, resulting in a complete response rate of 38% and an abscopal effect. Compared to B16F10 melanoma, better responsiveness to ECT was observed in more immunogenic 4%T1 mammary carcinoma and CT26 colorectal carcinoma. In both models, p. t. IL-12 GET did not significantly improve the therapeutic outcome of ECT using any of the chemotherapeutic drugs. Collectively, the effectiveness of the combination therapy depends on tumor immune status. ECT was more effective in more immunogenic tumors, but GET exhibited greater contribution in less immunogenic tumors. Thus, the selection of the therapy, namely, either ECT alone or combination therapy with p. t. IL-12, should be predominantly based on tumor immune status. Ključne besede: electrochemotherapy, gene electrotransfer, interleukin-12 Objavljeno v DiRROS: 21.09.2022; Ogledov: 696; Prenosov: 247 Celotno besedilo (7,82 MB) |
335. |
336. |
337. Poročilo o preskusu št.: LVG 2022-121 : vzorec št. 2022/00500/V1Nikica Ogris, Andreja Kavčič, Zina Devetak, Maša Zagorac, Barbara Piškur, 2022, izvedensko mnenje, arbitražna odločba Ključne besede: varstvo gozdov, morfološke analize, Geosmithia morbida, bolezen tisočerih rakov, Zeuzera pyrina, modro sitce Objavljeno v DiRROS: 21.09.2022; Ogledov: 497; Prenosov: 0 |
338. Poročilo o preskusu št.: LVG 2022-120 : vzorec št. 2022/00403Barbara Piškur, Špela Jagodic, Maša Zagorac, Nikica Ogris, 2022, izvedensko mnenje, arbitražna odločba Ključne besede: varstvo gozdov, morfološke analize, veliki pajesen, Ailanthus altissima, nekroza, izcedek, smola Objavljeno v DiRROS: 21.09.2022; Ogledov: 533; Prenosov: 0 |
339. |
340. BAP1-defficient breast cancer in a patient with BAP1 cancer syndromeAna Blatnik, Domen Ribnikar, Vita Šetrajčič Dragoš, Srdjan Novaković, Vida Stegel, Biljana Grčar-Kuzmanov, Nina Boc, Barbara Perić, Petra Škerl, Gašper Klančar, Mateja Krajc, 2022, izvirni znanstveni članek Povzetek: BAP1 cancer syndrome is a rare and highly penetrant hereditary cancer predisposition. Uveal melanoma, mesothelioma, renal cell carcinoma (RCC) and cutaneous melanoma are considered BAP1 cancer syndrome core cancers, whereas association with breast cancer has previously been suggested but not confirmed so far. In view of BAP1 immunomodulatory functions, BAP1 alterations could prove useful as possible biomarkers of response to immunotherapy in patients with BAP1-associated cancers. We present a case of a patient with BAP1 cancer syndrome who developed a metastatic breast cancer with loss of BAP1 demonstrated on immunohistochemistry. She carried a germline BAP1 likely pathogenic variant (c.898_899delAG p.(Arg300Glyfs*6)). In addition, tumor tissue sequencing identified a concurrent somatic variant in BAP1 (partial deletion of exon 12) and a low tumor mutational burden. As her triple negative tumor was shown to be PD-L1 positive, the patient was treated with combination of atezolizumab and nab-paclitaxel. She had a complete and sustained response to immunotherapy even after discontinuation of nab-paclitaxel. This case strengthens the evidence for including breast cancer in the BAP1 cancer syndrome tumor spectrum with implications for future cancer prevention programs. It also indicates immune checkpoint inhibitors might prove to be an effective treatment for BAP1-deficient breast cancer. Ključne besede: BAP1, breast cancer, hereditary cancer syndromes, immunotherapy Objavljeno v DiRROS: 19.09.2022; Ogledov: 546; Prenosov: 228 Celotno besedilo (1,12 MB) |